AR008765A1 - A PEPTIDE OR A DERIVATIVE, ANALOGUE OR VARIANT, FUNCTIONAL OF THE SAME, A RECOMBINANT OR SYNTHETIC PEPTIDE OF THE SAME, A NUCLEOTIDIC AND VECTOR CONTAINING SEQUENCE, A COMPUTER COMPOSITE, A PROCEDURE FOR ITS COMPOSITION, A COMPOSITE, A COMPOSITE OF THE - Google Patents
A PEPTIDE OR A DERIVATIVE, ANALOGUE OR VARIANT, FUNCTIONAL OF THE SAME, A RECOMBINANT OR SYNTHETIC PEPTIDE OF THE SAME, A NUCLEOTIDIC AND VECTOR CONTAINING SEQUENCE, A COMPUTER COMPOSITE, A PROCEDURE FOR ITS COMPOSITION, A COMPOSITE, A COMPOSITE OF THEInfo
- Publication number
- AR008765A1 AR008765A1 ARP970102432A ARP970102432A AR008765A1 AR 008765 A1 AR008765 A1 AR 008765A1 AR P970102432 A ARP970102432 A AR P970102432A AR P970102432 A ARP970102432 A AR P970102432A AR 008765 A1 AR008765 A1 AR 008765A1
- Authority
- AR
- Argentina
- Prior art keywords
- composite
- same
- peptide
- recombinant
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Child & Adolescent Psychology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un péptido o un derivado, análogo o variante funcional del mismo, que modula el peso corporal sustancialmente por medio de modulacion de lautilizacion de la energía, un péptido recombinante o sintético del mismo, una secuencia nucleotídica yvector que la contiene, una célula huéspedtransformada, una composicion farmacéutica que contiene un compuesto de este tipo, un procedimiento para la preparacionde un compuesto de este tipo y el usode dicho compuesto en medicina.A peptide or derivative, analog or functional variant thereof, that modulates body weight substantially by modulating energy utilization, a recombinant or synthetic peptide thereof, a nucleotide sequence and vector containing it, a transformed host cell, a a pharmaceutical composition containing such a compound, a process for the preparation of such a compound and the use of said compound in medicine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9611775.9A GB9611775D0 (en) | 1996-06-06 | 1996-06-06 | Novel compounds |
| GBGB9618540.0A GB9618540D0 (en) | 1996-09-05 | 1996-09-05 | Novel compounds |
| GBGB9703493.8A GB9703493D0 (en) | 1997-02-20 | 1997-02-20 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008765A1 true AR008765A1 (en) | 2000-02-23 |
Family
ID=27268305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970102432A AR008765A1 (en) | 1996-06-06 | 1997-06-04 | A PEPTIDE OR A DERIVATIVE, ANALOGUE OR VARIANT, FUNCTIONAL OF THE SAME, A RECOMBINANT OR SYNTHETIC PEPTIDE OF THE SAME, A NUCLEOTIDIC AND VECTOR CONTAINING SEQUENCE, A COMPUTER COMPOSITE, A PROCEDURE FOR ITS COMPOSITION, A COMPOSITE, A COMPOSITE OF THE |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0912609A2 (en) |
| JP (1) | JP2000512137A (en) |
| KR (1) | KR20000016402A (en) |
| CN (1) | CN1221426A (en) |
| AR (1) | AR008765A1 (en) |
| AU (1) | AU3337297A (en) |
| BR (1) | BR9709529A (en) |
| CA (1) | CA2257240A1 (en) |
| CZ (1) | CZ397898A3 (en) |
| IL (1) | IL127153A0 (en) |
| NO (1) | NO985683D0 (en) |
| NZ (1) | NZ332879A (en) |
| PL (1) | PL330361A1 (en) |
| TR (1) | TR199802534T2 (en) |
| WO (1) | WO1997046585A2 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2335107C (en) | 1998-07-28 | 2010-01-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Leptin-mediated gene-induction |
| US6777388B1 (en) | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| US7208572B2 (en) | 1998-08-21 | 2007-04-24 | Albany Medical College | Leptin-related peptides |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| CA2388417A1 (en) * | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| EP1283878B1 (en) | 2000-05-22 | 2005-07-27 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Receptor-based interaction trap |
| CA2464277C (en) | 2001-10-22 | 2013-02-05 | Amgen, Inc. | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| WO2005023288A1 (en) | 2003-09-08 | 2005-03-17 | Applied Research Systems Ars Holding N.V. | Treatment of fibrotic disease |
| EP2417980A1 (en) | 2004-02-11 | 2012-02-15 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| US8404637B2 (en) | 2005-02-11 | 2013-03-26 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| ES2319048B1 (en) * | 2007-06-20 | 2010-02-10 | Universitat De Les Illes Balears | USE OF LEPTINE IN THE TREATMENT OF ALTERATIONS IN FOOD HABITS. |
| US8889622B2 (en) | 2007-07-25 | 2014-11-18 | Washington University | Methods of inhibiting seizure in a subject |
| GB2451858A (en) * | 2007-08-15 | 2009-02-18 | Sergiy Konovchuk | Methods of reducing body fat and treating obesity |
| BRPI0820950A2 (en) | 2007-12-05 | 2015-07-07 | Astrazeneca Ab | Compound, pharmaceutical formulation, use of a compound, methods for treating or preventing conditions or diseases and for inhibiting angiogenesis, and process for preparing a compound. |
| CN102026975A (en) | 2007-12-05 | 2011-04-20 | 阿斯利康(瑞典)有限公司 | Piperazines as anti-obesity agents |
| CN102245183A (en) * | 2008-06-04 | 2011-11-16 | 阿斯利康(瑞典)有限公司 | New compounds v |
| WO2009147216A1 (en) * | 2008-06-04 | 2009-12-10 | Biovitrum Ab (Publ) | New pyridine derivatives as leptin receptor modulator mimetics |
| WO2010118384A2 (en) | 2009-04-10 | 2010-10-14 | Amylin Pharmaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
| WO2011143280A2 (en) * | 2010-05-11 | 2011-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling |
| DK2621519T3 (en) | 2010-09-28 | 2017-10-16 | Aegerion Pharmaceuticals Inc | Leptin-ABD fusion polypeptides with improved duration of action |
| CN104829707B (en) * | 2015-05-06 | 2017-12-19 | 广东省生物资源应用研究所 | The leptin activity peptide and its encoding gene and application of one CD ring and E spiral region mutations |
| CN110183530A (en) * | 2019-06-21 | 2019-08-30 | 深圳市亚辉龙生物科技股份有限公司 | Leptin immunogene, hybridoma, monoclonal antibody, polyclonal antibody and application |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| WO1996023815A1 (en) * | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Ob gene product antibodies |
| US5552523A (en) * | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996023514A1 (en) * | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
| AU5539596A (en) * | 1995-04-06 | 1996-10-23 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| GB9509164D0 (en) * | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
-
1997
- 1997-06-04 TR TR1998/02534T patent/TR199802534T2/en unknown
- 1997-06-04 CN CN97195311A patent/CN1221426A/en active Pending
- 1997-06-04 IL IL12715397A patent/IL127153A0/en unknown
- 1997-06-04 JP JP10500240A patent/JP2000512137A/en active Pending
- 1997-06-04 KR KR1019980709976A patent/KR20000016402A/en not_active Application Discontinuation
- 1997-06-04 AR ARP970102432A patent/AR008765A1/en unknown
- 1997-06-04 NZ NZ332879A patent/NZ332879A/en not_active IP Right Cessation
- 1997-06-04 CA CA002257240A patent/CA2257240A1/en not_active Abandoned
- 1997-06-04 WO PCT/EP1997/002968 patent/WO1997046585A2/en not_active Application Discontinuation
- 1997-06-04 PL PL97330361A patent/PL330361A1/en unknown
- 1997-06-04 CZ CZ983978A patent/CZ397898A3/en unknown
- 1997-06-04 BR BR9709529A patent/BR9709529A/en not_active Application Discontinuation
- 1997-06-04 AU AU33372/97A patent/AU3337297A/en not_active Abandoned
- 1997-06-04 EP EP97929156A patent/EP0912609A2/en not_active Withdrawn
-
1998
- 1998-12-04 NO NO985683A patent/NO985683D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997046585A3 (en) | 1998-04-23 |
| EP0912609A2 (en) | 1999-05-06 |
| PL330361A1 (en) | 1999-05-10 |
| NZ332879A (en) | 2000-09-29 |
| CN1221426A (en) | 1999-06-30 |
| JP2000512137A (en) | 2000-09-19 |
| TR199802534T2 (en) | 1999-03-22 |
| NO985683L (en) | 1998-12-04 |
| CZ397898A3 (en) | 1999-04-14 |
| IL127153A0 (en) | 1999-09-22 |
| NO985683D0 (en) | 1998-12-04 |
| KR20000016402A (en) | 2000-03-25 |
| AU3337297A (en) | 1998-01-05 |
| BR9709529A (en) | 1999-08-10 |
| CA2257240A1 (en) | 1997-12-11 |
| WO1997046585A2 (en) | 1997-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008765A1 (en) | A PEPTIDE OR A DERIVATIVE, ANALOGUE OR VARIANT, FUNCTIONAL OF THE SAME, A RECOMBINANT OR SYNTHETIC PEPTIDE OF THE SAME, A NUCLEOTIDIC AND VECTOR CONTAINING SEQUENCE, A COMPUTER COMPOSITE, A PROCEDURE FOR ITS COMPOSITION, A COMPOSITE, A COMPOSITE OF THE | |
| CO5700784A2 (en) | HUMAN PAPILOMA VIRUS POLIPEPTIDES AND IMMUNOGEN COMPOSITIONS | |
| DK2204187T3 (en) | Human influenza vaccine containing four influenza peptides | |
| CO4790174A1 (en) | ANALOGS OF PEPTIDE LH-RH, ITS USES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| ATE177757T1 (en) | IMPROVED IMMUNOGENIC COMPOSITION AGAINST HUMAN GASTRIN 17 | |
| RS51602B (en) | April receptor (bcma) and uses thereof | |
| HUP0003314A2 (en) | Use of glp-1 analogs and derivatives for preparing pharmaceutical compositions useful in regulation of obesity | |
| ES2187756T3 (en) | USE OF A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN APPETIZER SUPPRESSING PEPTIDE. | |
| CO5170453A1 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ACID (-) (3-TRIHALOMETOXI) (4-HALOPHENYL) ACETIC AND METFORMIN | |
| ES2052729T3 (en) | A PROCEDURE FOR APPLYING A COMPOSITE COATING TO A SUBSTRATE. | |
| HUP0100928A2 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
| ES2178000T3 (en) | COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS. | |
| AR002024A1 (en) | USEFUL PROTEINS FOR THE TREATMENT OF OBESITY, PHARMACEUTICAL COMPOSITIONS INCLUDING SUCH PROTEINS FOR ANTI-OBESITY TREATMENTS AND PROCEDURE TO PREPARE THEM. | |
| HK1040738A1 (en) | Human parathyroid hormone modifications, preparation and use | |
| BR9807618A (en) | Xdelta factor analogue, recombinant DNA encoding an xdelta factor analogue, transformed cells, preparation, use thereof, and processes for producing a preparation containing purified recombinant factor xdelta analogue and factor xa analogue. | |
| AR008094A1 (en) | PROCESS FOR THE SYNTHESIS OF A SYNTHETIC POLYPEPTIDE ANALOGED TO PARATHYROID HORMONE OR PEPTIDE RELATED TO PARATHYROID HORMONE AND PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION. | |
| AR002742A1 (en) | ADIPOSE TYPE REGULATORY PROTEIN, PROCEDURE TO PRODUCE SUCH PROTEIN, PHARMACEUTICAL FORMULATIONS INCLUDING IT, ISOLATED DNA MOLECULES THAT CODES SUCH PROTEIN, VECTOR AND RECOMBINANT CELLS THAT INCLUDE SUCH DNA | |
| AR024742A1 (en) | CYCLOPEPTIDIC DERIVATIVES THAT ACT AS INHIBITORS OF THE INTEGRIN ALFA v BETA 6, THE MEDICINES BASED ON THESE COMPOUNDS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THESE MEDICATIONS, AND THE USE OF THESE PERMITTED PREPARATIONS. | |
| ES2133295T3 (en) | CYCLIC PEPTIDES AND THEIR USE. | |
| DK1014948T3 (en) | Lyophilized pharmaceutical composition intended to mimic a drug based on proteins or polypeptides | |
| DK527187A (en) | GONADOLIBERINE ANALOGUE, PROCEDURE FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | |
| CO5271650A1 (en) | MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY | |
| EP0717752A4 (en) | Therapeutic compounds | |
| FI942392A0 (en) | Peptides and antibodies for the treatment of rheumatoid arthritis | |
| ES2160594T3 (en) | PROTECTIVE ANTIGENS AGAINST INFECTION WITH ECHINOCOCCUS GRANULOSUS AND VACCINES CONTAINING THESE ANTIGENS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |